KIDRON NADAV 4/A
4/A · ORAMED PHARMACEUTICALS INC. · Filed Jan 11, 2022
Insider Transaction Report
Form 4/AAmended
KIDRON NADAV
DirectorPresident and CEO
Transactions
- Award
Common Stock
2022-01-03+150,000→ 916,481 total - Tax Payment
Common Stock
2022-01-03$13.89/sh−48,752$677,165→ 867,729 total - Award
Common Stock
2022-01-03+63,000→ 930,729 total - Award
Stock Option (right to buy
2022-01-03+107,000→ 107,000 totalExercise: $13.89Exp: 2032-01-03→ Common Stock (107,000 underlying)
Footnotes (5)
- [F1]Represents Common Stock granted by the Issuer that vested upon grant.
- [F2]Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022.
- [F3]Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
- [F4]This amendment is being filed to correct an administrative error in the Form 4 filed by Mr. Kidron, which reported that 950,729 shares of common stock are beneficially owned by him following the reported transactions. Mr. Kidron beneficially owned 930,729 shares of common stock following the reported transactions.
- [F5]The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.